<?xml version="1.0" encoding="UTF-8"?>
<p>Renin–angiotensin–aldosterone system (RAAS)-related drugs (such as ACE inhibitors and angiotensin II receptor blockers, ARBs) are a cornerstone of therapy after MI, since maintenance of therapy in the days to weeks after the index event has been shown to reduce early mortality [
 <xref rid="B106-jcm-09-01683" ref-type="bibr">106</xref>]. Despite a lack of evidence of drug consumption or discontinuation in these patients included in the previous mentioned studies, it has been hypothesized that abrupt withdrawal of RAAS inhibitors in high-risk patients, especially those who have heart failure or previous MI, may result in clinical instability and adverse outcomes [
 <xref rid="B107-jcm-09-01683" ref-type="bibr">107</xref>,
 <xref rid="B108-jcm-09-01683" ref-type="bibr">108</xref>] and may eventually be related to myocardial injury.
</p>
